Stock Detail
PONIARD PHARMACEUTICALS INC
PARD @ Yahoo Finance | PARD Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $0.12 | $0.14 | $0.00 | 0.00% | 0.00 | $0.13 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.13 | $0.12 | 183,064 | 7.2M | 84,469 | -0.39 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 0.15 | 0.14 | 0.13 | 0.12 | 0.11 |
Stock Profile
Poniard Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of cancer therapy products in the United States. Its lead product is Picoplatin, a platinum-based cancer therapy, designed to overcome platinum resistance in the treatment of solid tumors. Picoplatin is in Phase II clinical trails in small cell lung cancer and is in Phase I/II trials for colorectal and hormone-refractory prostate cancers. The company has a collaboration agreement with The Scripps Research Institute on the discovery of novel, small-molecule, and multi-targeted protein kinase inhibitors and focal adhesion kinase inhibitors as therapeutic agents, including for the treatment of cancer. Poniard Pharmaceuticals was founded in 1984. It was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in 2006. The company is headquartered in South San Francisco, California.